Zomedica Corp. (NASDAQ:ZOM)

COMMUNIQUÉ DE PRESSE

publié le 04/01/2024 à 12:30, il y a 2 années 7 mois

Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website.

Zomedica Corp PulseVet Electro-hydraulic Shock Wave Therapy Veterinary Health Company Canine Patients Electro-hydraulic Shock Wave Therapy
COMMUNIQUÉ DE PRESSE

publié le 18/12/2023 à 12:30, il y a 2 années 8 mois

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
COMMUNIQUÉ DE PRESSE

publié le 06/12/2023 à 12:30, il y a 2 années 8 mois

Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
Zomedica announces presentation of clinical data in support of new indications for Pulsevet shock wave therapy at annual meeting of American Association of Equine Practitioners

Zomedica Pulsevet Shock Wave Therapy Veterinary Health Clinical Data
COMMUNIQUÉ DE PRESSE

publié le 28/11/2023 à 12:30, il y a 2 années 8 mois

Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
COMMUNIQUÉ DE PRESSE

publié le 20/11/2023 à 12:30, il y a 2 années 9 mois

Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
COMMUNIQUÉ DE PRESSE

publié le 13/11/2023 à 22:20, il y a 2 années 9 mois

Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
COMMUNIQUÉ DE PRESSE

publié le 02/11/2023 à 11:30, il y a 2 années 9 mois

Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
COMMUNIQUÉ DE PRESSE

publié le 10/10/2023 à 06:00, il y a 2 années 10 mois

Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
COMMUNIQUÉ DE PRESSE

publié le 05/10/2023 à 12:30, il y a 2 années 10 mois

Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
COMMUNIQUÉ DE PRESSE

publié le 14/09/2023 à 12:30, il y a 2 années 11 mois

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses

Publié le 21/08/2026 à 08:30, il y a 8 heures 12 minutes

Thales issues a €1bn bond
Publié le 21/08/2026 à 08:30, il y a 8 heures 12 minutes

Thales émet un emprunt obligataire de 1 Md€
Publié le 18/08/2026 à 18:00, il y a 2 jours 22 heures

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Publié le 18/08/2026 à 17:45, il y a 2 jours 22 heures

Mise à disposition du rapport financier annuel 2025-26
Publié le 18/08/2026 à 11:15, il y a 3 jours 5 heures

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026

Voir tout LES ECHOS COMFI WIRE

Publié le 21/08/2026 à 13:30, il y a 3 heures 12 minutes

BULGOLD Announces Filing Of Financial Results For the Six Months Ended June 30, 2026
Publié le 21/08/2026 à 02:30, il y a 14 heures 12 minutes

PPX Mining Announces Completion of Debt Settlement
Publié le 21/08/2026 à 00:00, il y a 16 heures 42 minutes

Apex Confirms Favourable Monazite and Bastnaesite Mineralogy at the Rift Rare Earth Project
Publié le 20/08/2026 à 23:00, il y a 17 heures 42 minutes

EQ Inc. Reports Second Quarter 2026 Financial Results
Publié le 20/08/2026 à 22:00, il y a 18 heures 42 minutes

Gold Terra Closes Third and Final Tranche of Its LIFE Offering for Gross Proceeds of Approximately C$10.1 M

Voir tout ACCESSWIRE

Publié le 21/08/2026 à 16:30, il y a 12 minutes

BL Networks (BLNWX) Details Major Global Infrastructure Expansion and Upgrades
Publié le 21/08/2026 à 15:23, il y a 1 heure 19 minutes

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Publié le 21/08/2026 à 15:22, il y a 1 heure 20 minutes

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Publié le 21/08/2026 à 15:21, il y a 1 heure 21 minutes

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Publié le 21/08/2026 à 15:18, il y a 1 heure 24 minutes

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

Voir tout EQS

News